A Study of AZD4205 in Healthy Adult Subjects

Phase 1 Completed 66 enrolled Dizal Pharmaceuticals

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is to assess the safety, tolerability, pharmacokinetics of AZD4205 following single and multiple ascending dose in healthy adult subjects, and to assess the effect of food on the pharmacokinetics of AZD4205.

Timeline

Start: 2018-11-12
Primary completion: 2019-08-20
Completion: 2019-08-20

Publications

Chen K, Guan X, Yang Z, Zhou Y, Liu Z, Deng X, Liu D, Hu P, Chen R. Pharmacokinetic characteristics of golidocitinib, a highly selective JAK1 inhibitor, in healthy adult participants. Front Immunol. 2023 Apr 3;14:1127935. doi: 10.3389/fimmu.2023.1127935. eCollection 2023.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Golidocitinib	Small molecule	5 mg	Oral
Subject	Golidocitinib	Small molecule	20 mg	Oral
Subject	Golidocitinib	Small molecule	50 mg	Oral
Subject	Golidocitinib	Small molecule	100 mg	Oral
Subject	Golidocitinib	Small molecule	150 mg	Oral

Indications

No indication recorded.